false
0001377121
0001377121
2024-01-31
2024-01-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d)
of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported): January 31, 2024
PROTAGONIST THERAPEUTICS, INC.
(Exact name of registrant as specified
in its charter)
Delaware |
|
001-37852 |
|
98-0505495 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark, California 94560-1160
(Address of principal executive offices,
including zip code)
(510) 474-0170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, par value $0.00001 |
|
PTGX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01. Entry into a Material
Definitive Agreement
Collaboration and License Agreement
On January 31, 2024, Protagonist Therapeutics,
Inc. (the “Company”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”)
with Takeda Pharmaceuticals USA, Inc. (“Takeda”) for the development, manufacture and commercialization of the Company’s
rusfertide product candidate (“Rusfertide”) and other specified second-generation injectable hepcidin mimetic compounds
(the “Licensed Products”). The Collaboration Agreement will become effective (the “Effective Date”)
upon the receipt of clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Collaboration and Licenses. The Company
and Takeda have agreed that the parties will, as further described below, jointly develop and commercialize the Licensed Products in the
United States (the “Profit-Share Territory”) and that Takeda solely and exclusively will develop and commercialize
the Licensed Products in all other countries (the “Takeda Territory”). Each of the Company and Takeda is obligated
to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in the Profit-Share Territory, and Takeda
is also obligated to use commercially reasonable efforts to develop and commercialize at least one Licensed Product in major regions of
the Takeda Territory.
The Company and Takeda have agreed to share
costs of the development, manufacture and commercialization activities for the Licensed Products under the Collaboration Agreement in
the Profit-Share Territory, provided that (i) the Company will lead, and will be responsible for its costs associated with, completion
of the ongoing Phase 3 VERIFY program evaluating Rusfertide for the treatment of Polycythemia Vera (the “VERIFY Program”);
(ii) Takeda will lead, and will be responsible for its costs associated with, pre-commercialization activities related to Rusfertide in
the Profit-Share Territory, and (iii) Takeda will lead commercialization of rusfertide globally, with Protagonist holding an option to
co-detail in the U.S. Takeda is solely responsible for all costs for the development, manufacture and commercialization activities under
the Collaboration Agreement in the Takeda Territory, and will have sole responsibility and decision-making authority with respect to such
activities in the Takeda Territory.
The Company has agreed to grant to Takeda
a non-transferable, sublicensable, except for certain specified exceptions, license to certain intellectual property of the
Company as needed to perform the activities under the Collaboration Agreement. Such license is co-exclusive with the Company
in the Profit-Share Territory and exclusive, even as to the Company, in the Takeda Territory, subject to certain retained rights to allow
the Company to exercise its rights and perform its obligations under the Collaboration Agreement.
Financial Terms; Opt-out Rights.
Upfront Payment; Profit Share;
Booking of Revenues. Under the terms of the Collaboration Agreement, Takeda has agreed to pay the Company an upfront payment of $300 million
within 30 days after the Effective Date. For so long as a Licensed Product is being sold in the Profit-Share Territory, the Company and
Takeda will share in all operating profits and losses arising from such Licensed Product in the Profit-Share Territory (50 percent to
the Company and 50 percent to Takeda) as further defined in the Collaboration Agreement. The Collaboration Agreement provides that Takeda
will book sales of Licensed Products globally.
Royalties. Takeda has agreed
to pay the Company tiered royalties of 10% – 17% on net sales of Licensed Products in the Takeda Territory. If the Company has exercised
an Opt-out Right (as defined below), Takeda has agreed to pay the Company royalties of 14% – 29% on worldwide net sales of Licensed
Products with respect to which the Company has exercised an Opt-out Right. Royalty payments may be reduced in certain specified circumstances.
Milestone Payments; Opt-out Payment.
The Collaboration Agreement provides for aggregate development, regulatory and commercial milestone payments from Takeda to the Company
for Licensed Products of (i) up to $330 million if the Company does not exercise an Opt-out Right and remains in the 50:50 profit-
and loss-sharing arrangement in the Profit-Share Territory; and (ii) up to $975 million if the Company exercises the Full Opt-out Right
(as defined below). Milestone payments as to Licensed Products other than Rusfertide may be reduced in certain specified circumstances.
In addition to the milestone payments
described above, in the event the Company exercises the Full Opt-out Right during the Initial Opt-out Period (as defined below), the Company
will receive: (a) a $200 million payment following its exercise of the Full Opt-out Right, and (b) an additional $200 million payment
following FDA approval of the New Drug Application for Rusfertide for polycythemia vera (together, the “Opt-out Payment”).
Opt-out Rights. The Company
will have the right to opt-out entirely of profit- and loss-sharing in the Profit-Share Territory as to all Licensed Products (the “Full
Opt-out Right”) during the 90-day period beginning 120 days after filing of a New Drug Application with the United States Food
and Drug Administration for Rusfertide for Polycythemia Vera (the “Initial Opt-out Period”); and (ii) for convenience
without receipt of the Opt-out Payment (generally following the Initial Opt-out Period). In addition, if the Company does not exercise
the Full Opt-out Right, the Company may opt-out of profit- and loss-sharing in the Profit-Share Territory as to Licensed Products other
than Rusfertide on a Licensed Product-by-Licensed Product basis (each, a “Partial Opt-out Right” and either the Full
Opt-out Right or a Partial Opt-out right being an “Opt-out Right”). Following the Company’s exercise of an Opt-out
Right, the Company has agreed to transition to Takeda applicable development and commercial activities, and Takeda has agreed to assume
sole operational and financial responsibility for such activities.
Governance. The activities of the parties
for the Profit-Share Territory are to be conducted pursuant to joint development plans and joint commercialization plans, on a Licensed Product-by-Licensed Product
basis, and overseen by a joint steering committee (the “JSC”) and various subcommittees, including a Joint Commercialization
Committee and a Joint Development Committee. The JSC shall be composed of an equal number of representatives from each of the Company
and Takeda.
Exclusivity; Right of First Negotiation.
During the term of the Collaboration Agreement, neither party nor any of its respective affiliates is permitted outside of the Collaboration
Agreement to directly or indirectly develop, manufacture, or commercialize injectable hepcidin mimetic products beyond agreed-upon stages
of development (pre-clinical in vitro research activities in the case of the Company, and up to Phase 2b clinical development in
the case of Takeda, respectively are permitted). In addition, the Company has granted to Takeda a 120-day right of first negotiation with
respect to other Company products in the hepcidin pathway.
Termination. Unless earlier terminated,
the Collaboration Agreement expires on a Licensed Product-by-Licensed Product and country-by-country basis on the
later of (a) in the Takeda Territory, the expiration of the royalty term for such Licensed Product in such country or (b) in
the Profit-Share Territory, until the parties agree to permanently stop commercializing such Licensed Product. Takeda may terminate the
Collaboration Agreement for convenience in its entirety or as to a major region by providing advance written notice following the earliest
of (i) the receipt of Phase 3 data with respect to the VERIFY Program, (ii) the third anniversary of the Effective Date or (iii) upon
the occurrence of certain specified adverse events related to the clinical development of Rusfertide. Either party may terminate the Collaboration
Agreement in its entirety (A) in the event of a material breach by the other party, subject to a cure period and (B) in the
event of the insolvency of the other party, in each case subject to specified conditions.
The foregoing description of the terms of
the Collaboration Agreement is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which
the Company intends to file with the U.S. Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on
Form 10-Q for the quarter ending March 31, 2024.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Protagonist Therapeutics, Inc. |
|
|
Dated: January 31, 2024 |
|
|
|
|
By: |
/s/ Asif Ali |
|
Asif Ali |
|
|
Chief Financial Officer |
v3.24.0.1
Cover
|
Jan. 31, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 31, 2024
|
Entity File Number |
001-37852
|
Entity Registrant Name |
PROTAGONIST THERAPEUTICS, INC.
|
Entity Central Index Key |
0001377121
|
Entity Tax Identification Number |
98-0505495
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
7707 Gateway Blvd.
|
Entity Address, Address Line Two |
Suite 140
|
Entity Address, City or Town |
Newark
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94560-1160
|
City Area Code |
510
|
Local Phone Number |
474-0170
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, par value $0.00001
|
Trading Symbol |
PTGX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Protagonist Therapeutics (NASDAQ:PTGX)
過去 株価チャート
から 4 2024 まで 5 2024
Protagonist Therapeutics (NASDAQ:PTGX)
過去 株価チャート
から 5 2023 まで 5 2024